Even though miR-301b may not be primarily working through PKD3, our findings show that PKD3 inhibition is a promising option for future therapeutics, with CRT0066101 having already been shown to inhibit tumor growth both in vitro and in vivo in several other cancer types (62–65). Here, PRKD3 is linked to neoplasm.